Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

This study has been terminated.
Information provided by (Responsible Party):
Hemispherx Biopharma Identifier:
First received: May 3, 2002
Last updated: April 16, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2005
  Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)